- Home
- LPSN vs HOWL Comparison
LPSN vs HOWL Comparison
Compare LPSN & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPSN | HOWL |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3M | 30.7M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPSN | HOWL |
|---|---|---|
| Price | $2.31 | $0.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 111.1K | ★ 629.3K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,838,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.40 |
| 52 Week High | $7.54 | $2.23 |
Technical Indicators
Market Signals| Indicator | LPSN | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 32.79 |
| Support Level | $0.88 | $0.40 |
| Resistance Level | $2.78 | $0.76 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 57.06 | 15.97 |
Price Performance
Historical ComparisonAbout LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.